GLP-1 Receptor Agonists and Cancer Risk

Introduction to GLP-1 Receptor Agonist Safety

The American College of Cardiology recommends evaluating time since remission and implementing close monitoring with regular thyroid function tests for patients with non-MTC thyroid cancer history who are prescribed GLP-1 RAs 2
GLP-1 receptor agonists are contraindicated only in patients with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2), but there is no conclusive evidence linking these medications to increased risk of other cancers including non-medullary thyroid cancer, pancreatic cancer, or breast cancer 1, 2

The FDA Black Box Warning specifically addresses thyroid C-cell tumors (medullary thyroid carcinoma), making GLP-1 RAs absolutely contraindicated in patients with personal or family history of MTC or MEN2 2

The American Heart Association and Heart Failure Society of America do not list breast cancer as a concern when prescribing GLP-1 RAs, with primary safety concerns limited to gastrointestinal effects, thyroid C-cell tumors (MTC only), and cardiovascular effects 1
Major cardiovascular guidelines do not identify breast cancer as a safety concern with GLP-1 RA therapy 1
The EXSCEL trial specifically reported that pancreatic cancer incidence did not differ significantly between exenatide and placebo groups 3

Before initiating GLP-1 RA therapy, screen for absolute contraindications, including personal history of medullary thyroid carcinoma, family history of medullary thyroid carcinoma, and multiple endocrine neoplasia syndrome type 2, and do not prescribe GLP-1 RAs in these cases 2
For patients with non-MTC thyroid cancer history, assess time since complete remission and implement regular thyroid function monitoring, and GLP-1 RAs can be used 2
For all other cancer concerns, proceed with standard GLP-1 RA prescribing, follow routine cancer screening guidelines for age and sex, and monitor for gastrointestinal side effects, gallbladder disorders, and tachycardia (the actual safety concerns) 1